Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.

Olga ProkopchukBarbara GrünwaldUlrich NitscheCarsten JägerOleksii L ProkopchukElaine C SchubertHelmut FriessMarc E MartignoniAchim Krüger

Published in: BMC cancer (2018)

This retrospective study reports for the first time that plasma levels of TIMP-1 are associated with pancreatic lesion-induced cachexia in patients without jaundice. TIMP-1 is counterindicated as a survival marker in patients with jaundice.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
high glucose
emergency department
oxidative stress
adverse drug